Related Experiment Video
Updated: Jan 15, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
DMPS-induced neurological deterioration in neurological Wilson's disease patients: a retrospective case-control study
Yannan Gao1,2, Jing Zhang2, Lulu Tang2
1Department of Neurology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Background And Aim:
Wilson's disease (WD), an autosomal recessive copper metabolism defect, causes pathological copper deposition in hepatic and neurological systems, culminating in cirrhosis and neuropsychiatric manifestations. Our understanding of neurological deterioration in neurological WD patients following sodium dimercaptopropanesulfonate (DMPS) treatment is limited. Thus, this study aims to analyze the phenotypic spectrum and predictors of DMPS-induced neurological deterioration in neurological WD.
Methods:
Demographic (age, gender, weight), clinical (K-F ring, duration of illness), and biochemical parameters [alanine aminotransferase, aspartate aminotransferase, albumin, serum ceruloplasmin, blood urea nitrogen, serum creatinine, 24 h urinary copper, lactate, homocysteine (HCY)] were systematically evaluated alongside neuroimaging data, followed by receiver operating characteristic (ROC) curve analysis to identify predictive biomarkers for neurological deterioration in DMPS-induced neurological WD patients.
Results:
A total of 277 neurological WD patients were enrolled, among whom 24.5% (68/277) developed neurological deterioration. Notably, 70.6% (48/68) of the patients experiencing neurological worsening were male. Among the patients, 91.2% (62/68) exhibited mild deterioration, while 8.8% (6/68) experienced severe deterioration. Multivariate logistic regression analysis indicated that sex [odds ratio (OR) = 0.41[95% confidence interval (CI) = 0.18-0.94], p = 0.035], brain Magnetic Resonance Imaging (MRI) score (OR = 2.89[95% CI = 1.99-4.21], p < 0.001), and HCY (OR = 1.45[95% CI = 1.27-1.65], p < 0.001) were associated with neurological deterioration. Subgroup analysis revealed statistically significant differences in male proportion (36/19 vs. 75/84, p = 0.019), brain MRI score (median: 5 vs. 4, p < 0.001), and HCY levels (mean: 20.75 vs. 17.77, p < 0.001) between the deterioration and non-deterioration groups within the under-35 cohort. ROC analysis of composite biomarkers demonstrated significant predictive capacity for neurological deterioration in DMPS-induced neurological WD (AUC = 0.862).
Conclusion:
Neurological deterioration in DMPS-induced neurological WD patients is not rare and predominantly occurs in males. We identified three independent risk factors for this deterioration: sex, brain MRI score, and HCY. A composite risk model incorporating these parameters achieved superior predictive accuracy compared to individual biomarker.
Related Concept Videos
Parkinson's Disease: Overview
Cardiomyopathy II: Dilated Cardiomyopathy
Disorders of the Nervous Tissue
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

